1. Care pathways in atopic dermatitis: a retrospective population‐based cohort study. (18th May 2022) Authors: von Kobyletzki, L.; Ballardini, N.; Henrohn, D.; Neary, M.P.; Ortsäter, G.; Geale, K.; Rieem Dun, A.; Lindberg, I.; De Geer, A.; Neregård, P.; Cha, A.; Cappelleri, J.C.; Romero, W.; Thyssen, J.P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 9(2022) Page Start: 1456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis. (12th June 2021) Authors: Silverberg, J.I.; Thyssen, J.P.; Fahrbach, K.; Mickle, K.; Cappelleri, J.C.; Romero, W.; Cameron, M.C.; Myers, D.E.; Clibborn, C.; DiBonaventura, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 9(2021) Page Start: 1797 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. High threshold efficacy responses in moderate‐to‐severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. (6th May 2022) Authors: Ständer, S.; Bhatia, N.; Gooderham, M. J.; Silverberg, J. I.; Thyssen, J. P.; Biswas, P.; DiBonaventura, M.; Romero, W.; Farooqui, S. A. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 8(2022) Page Start: 1308 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗